全部

1·Neonatal pulmonary hyaline membrane disease is a serious disease in the early newborn.

新生儿肺透明膜病是新生儿早期的严重疾病。

2·OBJECTIVE to investigate the way to increase the survival from the hyaline membrane disease.

目的探讨提高新生儿肺透明膜病生存率的方法。

3·Objective:To explore the effect of mechanical ventilation (MV) on premature infants with hyaline membrane disease (HMD )and its problems.

目的探讨分析应用机械通气治疗早产儿肺透明膜病（HMD）近期效果及存在的问题。

4·Purpose To evaluate the effects of ambroxol on prevention of premature babies with hyaline membrane disease(HMD) with prenatal corticosteroids.

目的探讨在应用肾上腺皮质激素的基础上加用沐舒坦预防早产儿肺透明膜病（HMD）的效果。

5·CONCLUSIONS Good curing, nursing care and quality control for nosocomial infection will increase the survival from the hyaline membrane disease.

结论合适的治疗方法、有效的护理措施和医院感染控制可提高患儿的生存率。

6·Conclusion (1) The incidence of wet lung of newborn and hyaline membrane disease will be increased in neonates delivered by elective caesarean section.

结论(1)选择性剖宫产新生儿湿肺、肺透明膜病等的发生率上升。

7·Objective To analyze the effect of breathing support of nasal continuous positive airway pressure (NCPAP) in hyaline membrane disease (HMD) of the newborn.

目的探讨鼻塞式持续气道正压通气(NCPAP)在新生儿肺透明膜病中的呼吸支持作用及其护理。

8·Objective To explore the effect of pulmonary surfactant (PS) combined with mechanical ventilation on pulmonary hyaline membrane disease of newborn (HMD) in newborn.

目的探讨肺表面活性物质（PS）与机械通气联用治疗新生儿肺透明膜病（HMD）的疗效及临床价值。

9·Objectives To study the expression of surfactant protein B(SP-B)and thyroid transcription factor 1(TTF-1)and evaluate the role in neonatal hyaline membrane disease(NHMD).

目的探讨表面活性蛋白B（SP-B）与甲状腺转录因子（TTF-1）在新生儿肺透明膜病中的表达及其意义。

10·Conclusion Pulmonary surfactant therapy in hyaline membrane disease of newborns can quickly correct the abnormal blood gas, and hence is worthy of being recommended in clinical practice.

结论肺表面活性物质治疗肺透明膜病，可以迅速纠正患者的血气指标异常，值得临床推广应用。